Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142278 | 1.00 | MAP4K4 (0.62) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL2142039 | 1.00 | MAP4K4 (0.62) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL2143634 | 0.86 | MAP4K4 (0.57) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL2126251 | 0.86 | MAP4K4 (0.57) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL2415078 | 0.83 | SMPD3 (0.46) | MAP4K4SUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL16620599 | 0.83 | MAP4K4 (0.59) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL16620602 | 0.83 | MAP4K4 (0.59) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL594137 | 0.83 | MAP4K4 (0.58) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL529863 | 0.83 | MAP4K4 (0.58) | MAP4K4PDE10ABTKSUV39H2AURKA | |
| SCHEMBL596151 | 0.83 | MAP4K4 (0.58) | MAP4K4PDE10ABTKSUV39H2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2424843-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | MAP4K4 137/4885PDE10A 1459/4885BTK 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.